Dr Boreham's Crucible: PolyNovo

Originally published by Biotech Daily, Friday March 27, 2026 - Biotech Daily

Polynovo’s new CEO Bruce Peatey has undertaken numerous ‘Mr Fix-it’ roles, in a medical device career spanning three decades, but says the burns and wounds house does not need to be repaired despite last year’s management’s turmoil.

Indeed, the company’s half-year results showed record revenue, so something is going right.

But it’s not a case of maintaining the status quo, either. While the company has done well with its initial burns indications - especially in the US - he believes management needs to do more to cement broader use of its Novosorb platform.

“We have a lot of potential and with a little capability and capacity in the right place, we can fire up that second engine of the business,” Mr Peatey says, referring to deep burns and wounds.

He is heartened by reports of surgeons using the company’s initial products, BTM and MTX, for numerous purposes (see below). “It’s very refreshing to be in a business growing [revenue by] 26 percent, a number of things have gone well,” he says.

“I’ve never seen so many levers you can pull to maintain growth.” Mr Peatey says the company is building up the formal evidence to crank start this second ‘engine’. This includes preparing a pre-market approval application to the US Food and Drug Administration (FDA), for full thickness burns.

Read the full article: Biotech Daily